Literature DB >> 11705718

Reaction time measures of sustained attention differentiate bipolar disorder from schizophrenia.

D E Fleck1, K W Sax, S M Strakowski.   

Abstract

Although continuous performance tasks (CPTs) are becoming more common in psychiatric research, it remains unclear which performance measures best differentiate psychiatric patient groups and along which psychological dimensions. To address this the authors examined sustained attention decrements in patients with bipolar disorder and schizophrenia using CPT measures of perceptual sensitivity, response bias, and psychomotor processing speed. Patients with bipolar disorder with psychotic features (N=20), schizophrenia (N=20), and healthy controls (N=20) were evaluated using structured clinical interviews. These patients were rated with the Scale for the Assessment of Positive Symptoms and the Young Mania Rating Scale before completing a degraded-stimulus version of the CPT. Psychomotor processing speed was the only measure that reliably differentiated the groups across the entire vigilance period and was the strongest predictor of group membership. These findings suggest that reaction time measures may be sensitive to differences in the sustained attention abilities of patients with bipolar disorder and schizophrenia. By incorporating reaction time measures into CPT assessments, discriminant ability may be enhanced.

Entities:  

Mesh:

Year:  2001        PMID: 11705718     DOI: 10.1016/s0920-9964(01)00170-0

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  14 in total

1.  Differential brain activation during response inhibition in bipolar and attention-deficit hyperactivity disorders.

Authors:  Michael A Cerullo; Caleb M Adler; Martine Lamy; James C Eliassen; David E Fleck; Stephen M Strakowski; Melissa P DelBello
Journal:  Early Interv Psychiatry       Date:  2009-08       Impact factor: 2.732

2.  Dissociation of acute and chronic intermittent phencyclidine-induced performance deficits in the 5-choice serial reaction time task: influence of clozapine.

Authors:  David M Thomson; Allan McVie; Brian J Morris; Judith A Pratt
Journal:  Psychopharmacology (Berl)       Date:  2010-09-29       Impact factor: 4.530

3.  Interacting mechanisms of impulsivity in bipolar disorder and antisocial personality disorder.

Authors:  Alan C Swann; Marijn Lijffijt; Scott D Lane; Joel L Steinberg; F Gerard Moeller
Journal:  J Psychiatr Res       Date:  2011-06-29       Impact factor: 4.791

4.  Impulsivity across the course of bipolar disorder.

Authors:  Stephen M Strakowski; David E Fleck; Melissa P DelBello; Caleb M Adler; Paula K Shear; Renu Kotwal; Stephan Arndt
Journal:  Bipolar Disord       Date:  2010-05       Impact factor: 6.744

5.  Antisocial personality and bipolar disorder: interactions in impulsivity and course of illness.

Authors:  Alan C Swann
Journal:  Neuropsychiatry (London)       Date:  2011

6.  Response selection in schizophrenia.

Authors:  Giuseppe Pellizzer; Massoud Stephane
Journal:  Exp Brain Res       Date:  2007-02-20       Impact factor: 1.972

7.  BRAIN MYELINATION IN PREVALENT NEUROPSYCHIATRIC DEVELOPMENTAL DISORDERS: PRIMARY AND COMORBID ADDICTION.

Authors:  George Bartzokis
Journal:  Adolesc Psychiatry       Date:  2005

8.  The schizophrenia phenotype in 22q11 deletion syndrome.

Authors:  Anne S Bassett; Eva W C Chow; Philip AbdelMalik; Mirona Gheorghiu; Janice Husted; Rosanna Weksberg
Journal:  Am J Psychiatry       Date:  2003-09       Impact factor: 18.112

9.  Characterizing impulsivity in mania.

Authors:  Stephen M Strakowski; David E Fleck; Melissa P DelBello; Caleb M Adler; Paula K Shear; Susan L McElroy; Paul E Keck; Quinton Moss; Michael A Cerullo; Renu Kotwal; Stephan Arndt
Journal:  Bipolar Disord       Date:  2009-02       Impact factor: 6.744

10.  Severity of bipolar disorder is associated with impairment of response inhibition.

Authors:  Alan C Swann; Marijn Lijffijt; Scott D Lane; Joel L Steinberg; F Gerard Moeller
Journal:  J Affect Disord       Date:  2008-11-26       Impact factor: 4.839

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.